Search This Blog

Sunday, November 15, 2026

FDA issues Complete Response Letter for Summit Therapeutics' ivonescimab lung cancer application

 citing no statistically significant overall-survival improvement

https://finviz.com/stock?t=SMMT&p=d

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.